US Federal House Bill HB1262

US Federal 2025-2026 Regular Session

• Introduced: 2/12/25
• Refer: 2/12/25
• Report Pass: 9/17/25
• Engrossed: 12/2/25

Caption

Mikaela Naylon Give Kids a Chance Act

Impact

If enacted, HB 1262 will significantly influence the landscape of pediatric oncology by facilitating expedited research and development processes for pediatric cancer drugs. It extends the authority of the FDA to issue priority review vouchers for treatments directed at rare pediatric diseases, thereby motivating pharmaceutical companies to invest in the development of these necessary therapies. The requirement for pediatric studies ensures that children receive medications that are both safe and effective, fostering an environment that prioritizes pediatric health in drug development efforts.

Summary

House Bill 1262, titled the Mikaela Naylon Give Kids a Chance Act, aims to enhance research concerning pediatric drug use, particularly in the context of molecularly targeted therapies for cancer. It amends the Federal Food, Drug, and Cosmetic Act to provide additional authorities to the FDA for conducting investigations into the efficacy and safety of cancer drugs specifically designed for pediatric patients. The bill emphasizes the importance of obtaining clinically meaningful data that can be utilized for pediatric labeling of therapies that address rare pediatric diseases, particularly cancers.

Sentiment

The sentiment towards HB 1262 appears to be largely positive among advocates of pediatric health, as it addresses critical gaps in research and development of drugs for children. Supporters argue that the bill will improve access to therapies that are often overlooked in favor of adult-focused research. However, there are concerns from some stakeholders regarding the balance between expedited approvals and the thoroughness of safety evaluations, reflecting a tension between urgency and safety in pediatric drug development.

Contention

While the overall intent of HB 1262 is broadly supported, contention may arise regarding the implications of expedited review processes. Critics may argue that prioritizing speed in drug approvals could compromise comprehensive evaluations, potentially placing children at risk if drugs are released without thorough testing tailored to their unique physiological needs. The effectiveness of the priority review vouchers in incentivizing research and their impact on market dynamics may also be subjects for debate, particularly regarding their utility in ensuring adequate treatment options for rare pediatric conditions.